A randomized, double-blind study on the efficacy of oral domperidone versus placebo for reducing SARS-CoV-2 viral load in mild-to-moderate COVID-19 patients in primary health care

References

• Mirabelli C, Wotring JW, Zhang CJ, et al. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19. Proc Natl Acad Sci U S A. 2021;118(36):1. doi: 10.1073/pnas.2105815118.
   Web of Science ®Google Scholar
• Martinez A, Gil C, Gastaminza P, et al. Domperidone for use as antiviral agent. EP3949965, WO2022028839, priority date 07/08/2020.
   Google Scholar
• Sen A. Repurposing prolactin as a promising immunomodulator for the treatment of COVD-19: are common antiemetics the wonder drug to fight coronavirus? Med Hypotheses. 2020;144:110208. doi: 10.1016/j.mehy.2020.110208.
   PubMed Web of Science ®Google Scholar
• De Bellis A, Bizzarro A, Pivonello R, et al. Prolactin and autoimmunity. Pituitary. 2005;8(1):25–13. doi: 10.1007/s11102-005-5082-5.
   PubMedGoogle Scholar
• Yu-Lee L-Y. Molecular actions of prolactin in the immune system. Proc Soc Exp Biol Med. 1997;215(1):35–52. doi: 10.3181/00379727-215-44111.
   PubMed Web of Science ®Google Scholar
• Borba VV, Zandman-Goddard G, Shoenfeld Y. Prolactin and autoimmunity. Front Immunol. 2018;9:73. doi: 10.3389/fimmu.2018.00073.
   PubMed Web of Science ®Google Scholar
• Pereira-Suarez AL, López-Rincón G, Neri PAM, et al. Prolactin in inflammatory response. Adv Exp Med Biol. 2015;846:243–264. doi: 10.1007/978-3-319-12114-7_11.
   PubMed Web of Science ®Google Scholar
• Sykes L, MacIntyre DA, Yap XJ, et al. Changes in the Th1:Th2 cytokine bias in pregnancy and the effects of the anti-inflammatory cyclopentenone prostaglandin 15-deoxy-Δ12,14-prostaglandin J2. Mediators Inflamm. 2012;2012:416739. doi: 10.1155/2012/416739.
   PubMed Web of Science ®Google Scholar
• Parra A, Ramírez-Peredo J, Reyes E, et al. Moderate hyperprolactinemia is associated with survival in patients with acute graft-versus-host disease after allogeneic stem cell transplantation. Hematology. 2012;17(2):85–92. doi: 10.1179/102453312X13221316477930.
   PubMed Web of Science ®Google Scholar
• Yu-Lee L-Y. Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res. 2002;57(1):435–455. doi: 10.1210/rp.57.1.435.
   PubMedGoogle Scholar
• Matalka KZ. Prolactin enhances production of interferon-gamma, interleukin-12, and interleukin-10, but not of tumor necrosis factor-alpha, in a stimulus-specific manner. Cytokine. 2003;21(4):187–194. doi: 10.1016/s1043-4666(02)00496-9.
   PubMed Web of Science ®Google Scholar
• Chuang E, Molitch ME. Prolactin and autoimmune diseases in humans. Acta Biomed. 2007;78(Suppl 1):255–261.
   PubMedGoogle Scholar
• Adán N, Guzmán-Morales J, Ledesma-Colunga MG, et al. Prolactin promotes cartilage survival and attenuates inflammation in inflammatory arthritis. J Clin Invest. 2013;123(9):3902–3913. doi: 10.1172/JCI69485.
   PubMed Web of Science ®Google Scholar
• Imrich R. The role of neuroendocrine system in the pathogenesis of rheumatic disease (minireview). Endocr Regul. 2002;36:95–106.
   PubMedGoogle Scholar
• Shelly S, Boaz M, Orbach H. Prolactin and autoimmunity. Autoimmun Rev. 2012;11(6–7):A465–A470. doi: 10.1016/j.autrev.2011.11.009.
   PubMed Web of Science ®Google Scholar
• Lucas A, Baker BA, Cole TJ. Plasma prolactin and clinical outcome in preterm infants. Arch Dis Child. 1990;65(9):977–983. doi: 10.1136/adc.65.9.977.
   PubMed Web of Science ®Google Scholar
• Zellweger R, Wichmann MW, Ayala A, et al. Metoclopramide: a novel and safe immunomodulating agent for restoring the depressed macrophage immune function after hemorrhage. J Trauma. 1998;44(1):70–77. doi: 10.1097/00005373-199801000-00006.
   PubMedGoogle Scholar
• Orlander H, Peter S, Jarvis M, et al. Imipramine induced elevation of prolactin levels in patients with HIV/AIDS improved their immune status. West Indian Med J. 2009;58(3):207–213.
   PubMed Web of Science ®Google Scholar
• Wu X, Liu Y, Guo X, et al. Prolactin inhibits the progression of intervertebral disc degeneration through inactivation of the NF-κB pathway in rats. Cell Death Dis. 2018;9(2):98. doi: 10.1038/s41419-017-0151-z.
   PubMedGoogle Scholar
• Ochoa-Amaya JE, Hamasato EK, Tobaruela CN, et al. Short-term hyperprolactinemia decreases allergic inflammatory response of the lungs. Life Sci. 2015;142:66–75. doi: 10.1016/j.lfs.2015.10.016.
   PubMed Web of Science ®Google Scholar
• Ochoa-Amaya JE, Marino LP, Tobaruela CN, et al. Attenuated allergic inflammatory response in the lungs during lactation. Life Sci. 2016;151:281–287. doi: 10.1016/j.lfs.2016.03.027.
   PubMed Web of Science ®Google Scholar
• López-Mesa JE, Lara-Zárate L, Ochoa-Zarzosa A. Effects of prolactin on innate immunity of infectious diseases. Open Neuroendocrinol J. 2010;3:175–179.
   Google Scholar
• Peña B, Isla A, Haussmann D, et al. Immunostimulatory effect of salmon prolactin on expression of toll-like receptors in Oncorhynchus mykiss infected with Piscirickettsia salmonis. Fish Physiol Biochem. 2016;42(2):509–516. doi: 10.1007/s10695-015-0155-5.
   PubMed Web of Science ®Google Scholar
• Cejkova P, Chroma V, Cerna M, et al. Monitoring of the course of sepsis in hematooncological patients by extrapituitary prolactin expression in peripheral blood monocytes. Physiol Res. 2012;61(5):481–488. doi: 10.33549/physiolres.932262.
   PubMed Web of Science ®Google Scholar
• Felmet KA, Hall MW, Clark RS, et al. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol. 2005;174(6):3765–3772. doi: 10.4049/jimmunol.174.6.3765.
   PubMed Web of Science ®Google Scholar
• Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Protocolo de Actuación en Pacientes con COVID-19 Asistidos en Atención Primaria. Madrid, Spain: Sociedad Española de Médicos de Atención Primaria (SEMERGEN); 2020. ISBN 978-84-16269-52-5. [cited 2022 Nov 22]. Available from: https://www.semergen.es/files/docs/COVID-19/Documentos/ferrer-covid-19.pdf
   Google Scholar
• World Health Organization. COVID-19 clinical management. This document is the update of an interim guidance originally published under the Title “Clinical management of COVID-19: interim guidance, 27 May 2020”. World Health Organization; 2021. (WHO reference number: WHO/2019-nCoV/clinical/2021.1). [cited 2022 Nov 22]. Available from: https://www.semergen.es/files/docs/COVID-19/Documentos/who-guide-covig192021.1-eng.pdf
   Google Scholar
• Rivasi G, Bulgaresi M, Mossello E, et al. Course and lethality of SARS-CoV-2 epidemic in nursing homes after vaccination in Florence, Italy. Vaccines. 2021;9(10):1174. doi: 10.3390/vaccines9101174.
   PubMed Web of Science ®Google Scholar
• Christie A, Mbaeyi SA, Walensky RP. CDC interim recommendations for fully vaccinated people: an important first step. JAMA. 2021;325(15):1501–1502. doi: 10.1001/jama.2021.4367.
   PubMed Web of Science ®Google Scholar
• Actualización de la Situación Epidemiológica de las Variantes SARS-CoV-2 en España. Ministerio de Sanidad; 2022 Sep 26 [cited 2022 No 22]. Available from: https://www.sanidad.gob.es/profesionales/saludPublica/ ccayes/alertasActual/nCov/documentos/COVID19_Actualizacion_variantes_20220926.pdf
   Google Scholar
• Chokkalingam AP, Hayden J, Goldman JD, et al. Association of remdesivir treatment with mortality among hospitalized adults with COVID-19 in the United States. JAMA Netw Open. 2022;5(12):e2244505. doi: 10.1001/jamanetworkopen.2022.44505.
   PubMed Web of Science ®Google Scholar
• Wen W, Chen C, Tang J, et al. Efficacy and safety or three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann Med. 2022;54(1):516–523. doi: 10.1080/0785389.2022.2034936.
   PubMed Web of Science ®Google Scholar
• Ashour N, Elmaaty AA, Sarhan AA, et al. A systematic review of the global intervention for SARS-CoV-2 combating: from drugs repurposing to molnupiravir approval. Drug Des Devel Ther. 2022;16:685–715. doi: 10.2147/DDDT.S354841.
   PubMed Web of Science ®Google Scholar
• Drożdżal S, Rosik J, Lechowicz K, et al. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resist Updat. 2021;59:100794. doi: 10.1016/j.drup.2021.100794.
   PubMed Web of Science ®Google Scholar
• Vila Méndez ML, Antón Sanz C, Cárdenas García AR, et al. Efficacy of bromhexine versus standard of care in reducing viral load in patients with mild-to-moderate COVID-19 disease attended in primary care: a randomized open-label trial. J Clin Med. 2022;12(1):142. doi: 10.3390/jcm12010142.
   PubMed Web of Science ®Google Scholar
• Ministerio de Sanidad. Enfermedad por coronavirus, COVID-19. Actualización 2020 Nov 12 [cited 2022 Nov 22]. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/ITCoronavirus/home.htm
   Google Scholar